https://www.millionsmissing.de/2025-04-14-broken-b
Post# of 154592
(Total Views: 656)
Posted On: 04/14/2025 5:59:13 PM
https://www.millionsmissing.de/2025-04-14-bro...#gsc.tab=0
unfortunately only in german:
Broken Bridge Syndrome: A new understanding and diagnostic marker for post-COVID syndrome (PCS) and ME/CFS?
....
10.2.1 Overview of treatment options
CCR5 antagonists (e.g. maraviroc, leronlimab)
These agents block the CCR5 receptor, a small protein on the surface of immune cells that is involved in controlling inflammatory processes.
In PCS and ME/CFS, it has been shown that this receptor is overactive in some patients, which can lead to chronic inflammation in the brain.
CCR5 antagonists such as maraviroc (originally used for HIV) can “switch
10.2.1 Overview of treatment options
CCR5 antagonists (e.g. maraviroc, leronlimab)
These agents block the CCR5 receptor, a small protein on the surface of immune cells that is involved in controlling inflammatory processes.
In PCS and ME/CFS, it has been shown that this receptor is overactive in some patients, which can lead to chronic inflammation in the brain.
CCR5 antagonists such as maraviroc (originally used for HIV) can “switch off” this receptor and thus slow down inflammatory overreactions.
In small pilot studies, for example at Stanford University, patients experienced noticeable improvements, e.g. in fatigue, cognition and circulatory dysregulation.
Leronlimab
A monoclonal antibody that also targets CCR5.
It was originally developed for HIV and cancer, but initial studies have shown that it is also effective in neuroinflammatory diseases.
According to Ziaja and his partners at Stanford, both substances could be particularly helpful for patients with matching autoantibodies or cytokine patterns.
Translated with DeepL.com (free version)
unfortunately only in german:
Broken Bridge Syndrome: A new understanding and diagnostic marker for post-COVID syndrome (PCS) and ME/CFS?
....
10.2.1 Overview of treatment options
CCR5 antagonists (e.g. maraviroc, leronlimab)
These agents block the CCR5 receptor, a small protein on the surface of immune cells that is involved in controlling inflammatory processes.
In PCS and ME/CFS, it has been shown that this receptor is overactive in some patients, which can lead to chronic inflammation in the brain.
CCR5 antagonists such as maraviroc (originally used for HIV) can “switch
10.2.1 Overview of treatment options
CCR5 antagonists (e.g. maraviroc, leronlimab)
These agents block the CCR5 receptor, a small protein on the surface of immune cells that is involved in controlling inflammatory processes.
In PCS and ME/CFS, it has been shown that this receptor is overactive in some patients, which can lead to chronic inflammation in the brain.
CCR5 antagonists such as maraviroc (originally used for HIV) can “switch off” this receptor and thus slow down inflammatory overreactions.
In small pilot studies, for example at Stanford University, patients experienced noticeable improvements, e.g. in fatigue, cognition and circulatory dysregulation.
Leronlimab
A monoclonal antibody that also targets CCR5.
It was originally developed for HIV and cancer, but initial studies have shown that it is also effective in neuroinflammatory diseases.
According to Ziaja and his partners at Stanford, both substances could be particularly helpful for patients with matching autoantibodies or cytokine patterns.
Translated with DeepL.com (free version)
(9)
(0)